Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 11, 2015, Pages 1929-1936.e1

  Theede, Klaus ^a   Holck, Susanne ^a   Ibsen, Per ^a   Ladelund, Steen ^a   Nordgaard Lassen, Inge ^a   Nielsen, Anette Mertz ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

IBD; Inflammatory Bowel Disease; Marker; Outcome

Indexed keywords

CALGRANULIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; FECES LEVEL; FEMALE; HEALING; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAYO ENDOSCOPIC SCORE; MUCOSAL HEALING; OBSERVATIONAL STUDY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; ULCERATIVE COLITIS; ULCERATIVE COLITIS ENDOSCOPIC INDEX OF SEVERITY; CHEMISTRY; COLITIS, ULCERATIVE; DENMARK; FECES; INFLAMMATION; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; UNIVERSITY HOSPITAL; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; COLITIS, ULCERATIVE; CROSS-SECTIONAL STUDIES; DENMARK; FECES; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INFLAMMATION; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SIGMOIDOSCOPY; YOUNG ADULT;

EID: 84944279049     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.05.038     Document Type: Article

References (32)

1. Røseth A.G., Schmidt P.N., Fagerhol M.K. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999, 34:50-54.
2. D'Haens G., Ferrante M., Vermeire S., et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2218-2224.
3. Schoepfer A.M., Beglinger C., Straumann A., et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009, 15:1851-1858.
4. Gisbert J.P., Bermejo F., Pérez-Calle J.-L., et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009, 15:1190-1198.
5. Costa F., Mumolo M.G., Ceccarelli L., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005, 54:364-368.
6. De Vos M., Dewit O., D'Haens G., et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis 2012, 6:557-562.
7. Ho G.T., Mowat C., Goddard C.J.R., et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004, 19:1079-1087.
8. Theede K., Kiszka-Kanowitz M., Mertz Nielsen A., et al. The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment. Scand J Gastroenterol 2014, 49:418-423.
9. Wright E.K., Kamm M.A., De Cruz P., et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease following surgery. Gastroenterology 2015, 148:938-947.
10. Lasson A., Stotzer P.-O., Öhman L., et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015, 9:26-32.
11. Kristensen V., Malmstrøm G.H., Skar V., et al. Clinical relevance of faecal calprotectin variability in Inflammatory Bowel Disease. Congr ECCO 2015, P320.
12. Frøslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
13. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011, 9:483-489.
14. Neurath M.F., Travis S.P.L. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012, 61:1619-1635.
15. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010, 16:338-346.
16. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987, 317:1625-1629.
17. Travis S.P.L., Schnell D., Krzeski P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012, 61:535-542.
18. Travis S.P.L., Schnell D., Krzeski P., et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013, 145:987-995.
19. Riley S., Mani V., Goodman M.J., et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991, 32:174-178.
20. Bessissow T., Lemmens B., Ferrante M., et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012, 107:1684-1692.
21. Mosli M.H., Feagan B.G., Sandborn W.J., et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014, 20:564-575.
22. Geboes K., Riddell R., Öst A., et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000, 47:404-409.
23. Fiel M., Qin L., Suriawinata A., et al. Histological grading of disease activity in chronic IBD: inter- and intra-observer variation among pathologists with different levels of experience. Mod Pathol 2003, 16:118A.
24. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105. quiz 1340-1341.
25. Hefti M.M., Chessin D.B., Harpaz N.H., et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 2009, 52:193-197.
26. Ricanek P., Brackmann S., Perminow G., et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 2011, 46:1081-1091.
27. Schoepfer A.M., Beglinger C., Straumann A., et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013, 19:332-341.
28. Taghvaei T., Maleki I., Nagshvar F., et al. Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Intern Emerg Med 2014, 10:321-328.
29. Lemmens B., Arijs I., Van Assche G., et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis 2013, 19:1194-1201.
30. Baars J.E., Nuij V.J.A.A., Oldenburg B., et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012, 18:1634-1640.
31. Peyrin-Biroulet L., Bressenot A., Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis?. Clin Gastroenterol Hepatol 2014, 12:929-934.
32. Guardiola J., Lobatón T., Rodríguez-Alonso L., et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol 2014, 12:1865-1870.